刘虹,滕涛,王燕,张纯全,夏伟,徐庆科

• 1:青岛市立医院东院心内科
• 2:青岛大学医学院附属医院东区心内科

摘要(Abstract)：

目的评价普罗布考对合并糖尿病的冠心病患者药物洗脱支架置入术后再狭窄发生率及炎症因子的影响,初步探讨普罗布考预防再狭窄的临床价值及可能机制。方法入选72例合并糖尿病并接受药物洗脱支架置入术的冠心病患者,随机分为普罗布考组(36例)和对照组(36例)。普罗布考组在常规药物的基础上加服普罗布考(0.25 g,每日2次),连续服药至PCI术后6个月,所有患者行冠状动脉造影复查。支架内再狭窄定义为支架内或两端5 mm内出现≥50%狭窄程度的病变。测定术前及术后6个月的血清超敏C反应蛋白、白细胞介素-6、肿瘤坏死因子-α的浓度变化。结果对照组中10例(27.8%)发生再狭窄,普罗布考组仅3例(8.3%)发生再狭窄,两组间比较,差异有统计学意义(P=0.032);术后6个月时两组患者炎症因子水平较术前均有下降,普罗布考组下降更显著,差异具有统计学意义(P<0.05)。结论普罗布考能够有效降低合并糖尿病的冠心病患者置入药物洗脱支架置入后再狭窄的发生,其机制可能与抗炎作用有关。

关键词(KeyWords)： 普罗布考;糖尿病;支架内再狭窄

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘虹,滕涛,王燕,张纯全,夏伟,徐庆科

参考文献(References)：

• [1]Garas SM,Huber P,Scott NA.Overview of therapies for prevention of restenosis after coronary interventions.Pharmacol Ther,2001,92:165-178.
• [2]苏林,刘学波,葛均波.糖尿病与冠脉支架再狭窄的关系分析.中国临床医学,2005,12:578-580.
• [3]金泽宁,陈韵岱,吕树铮,等.冠心病合并糖尿病患者金属裸支架置入术后再狭窄的临床和造影预测因素.中华心血管病杂志,2006,34:1093-1096.
• [4]Walter DH,Fichtlscherer S,Selwig M,et al.Preprocedural Creaction protein levels and cardiovascular events after coronary stent implantation.J Am Coil Cardiol,2001,37:839-846.
• [5]Ross R.Atherosclerosis—an inflammatory disease.N Engl J Med,1999,340:115-126.
• [6]黄炜,陈清枝,燕宪亮,等.C反应蛋白、白细胞介素-6和肿瘤坏死因子α在冠心病中的变化.临床心血管病杂志,2004,7:398-400.
• [7]王晓昕,赵红丽,李潞,等.普罗布考改善AMI患者PCI预后及炎症反应的临床研究.沈阳药学院学报,2008,3:10-12.
• [8]韩雅玲,刘海伟.2005美国经皮冠状动脉介入治疗指南.中国实用内科杂志,2007,27:86-88.
• [9]Lowe HC,Oesterle SN,Khachigian LM.Coronary in-stent restenosis:current status and future Strategies.J Am Coll Cardiol,2002,39:183-193.
• [10]Drachman DE,Simon DI.Inflammation as a mechanism and therapeutic target for in-stent restenosis.Curr Atheroscler Rep,2005,7:44-49.
• [11]Almagor M,Keren A,Banal S.Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease.Am Heart J,2003,145:248-253.
• [12]Dibra A,Mehilli J,Braun S,et al.Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.Am Heart J,2005,150:344-350.
• [13]Wildgruber M,Weiss W,Berger H,et al.Association of circulating transforming growth factor beta,tumor necrosis factor alpha and basic fibroblast growth factor with restenosis after transluminal angioplasty.Eur J Vasc Endovasc Surg,2007,34:35-43.
• [14]胡桃红,马会利,靳志涛,等.炎症因子对冠心病患者经皮冠状动脉介入术后支架再狭窄的影响.中国医药,2013,8:12-14.
• [15]Tardif JC,CotéG,Lespérance J,et al.Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.Multivitamins and Probucol Study Group.N End J Med,1997,337:365-372.
• [16]Kaminnyi AI,Lankin VZ,Samko AN,et al.Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty.Bull Exp Biol Med,2005,139:183-185.
• [17]王敬萍,安健,张悟棠,等.普罗布考与普伐他汀预防经皮冠状动脉介入治疗后再狭窄的对比研究.中国介入心脏病学杂志,2009,17:251-254.
• [18]彭雪梅,安永为,高晓东.普罗布考对糖尿病合并冠心病金属裸支架置入术后再狭窄预防的临床观察.中国心血管病研究,2008,6:426-428.
• [19]岳欣,潘其兴,张薇.普罗布考(Probucol)预防PTCA术后再狭窄的研究进展.心血管病学进展,2000,21:204-206.
• [20]薛鸿群,侯爱琴,陈亚君.普罗布考对急性心肌梗死介入术后炎性反应的干预作用.中国实用医刊,2011,38:60-61.